Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1147997 | 1.00 | FKBP1A (0.33) | FKBP1ANR1H2LRRK2 | |
| SCHEMBL12632024 | 0.90 | FKBP1A (0.33) | FKBP1A | |
| SCHEMBL8062803 | 0.90 | FKBP1A (0.33) | FKBP1A | |
| SCHEMBL23311099 | 0.89 | NR1H2 (0.32) | FKBP1ANR1H2 | |
| SCHEMBL62605 | 0.89 | NR1H2 (0.32) | FKBP1ANR1H2 | |
| SCHEMBL51492 | 0.89 | NR1H2 (0.32) | FKBP1ANR1H2 | |
| SCHEMBL31645669 | 0.85 | EPHX2 (0.34) | FKBP1ANR1H2 | |
| SCHEMBL13866331 | 0.85 | FKBP1A (0.33) | FKBP1ALRRK2 | |
| SCHEMBL18669498 | 0.85 | FKBP1A (0.33) | FKBP1ALRRK2 | |
| SCHEMBL13866332 | 0.85 | FKBP1A (0.33) | FKBP1ALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473284-B2 | Small molecule inhibitors of ULK1 | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250051347-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | Hinova Pharmaceuticals, Inc. (CN) | 2025-02-13 | — | — | US | disclosed |
| WO-2024238570-A1 | CDK2 INHIBITOR PYRAZOLOPYRIMIDINE COMPOUNDS | ALEKSIA THERAPEUTICS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| WO-2024192064-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A/ PROTEOVANT THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024173646-A1 | CYCLIN-DEPENDENT KINASE DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| EP-4378936-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | Hinova Pharmaceuticals Inc. (CN) | 2024-06-05 | — | — | EP | disclosed |
| EP-4271664-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230117572-A1 | SMALL MOLECULE INHIBITORS OF ULK1 | MEMORIAL SLOAN KETTERING CANCER CENTER | 2023-04-20 | — | — | US | disclosed |
| US-20230117572-A1 | SMALL MOLECULE INHIBITORS OF ULK1 | MEMORIAL SLOAN KETTERING CANCER CENTER | 2023-04-20 | — | — | US | disclosed |
| CN-115867534-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20030199550-A1 | Substituted cyclohexane derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2003-10-23 | — | — | US | disclosed |
| US-20030186984-A1 | Substituted cyclohexane derivatives | HOFFMAN-LA ROCHE INC. | 2003-10-02 | — | — | US | disclosed |
| US-20030186926-A1 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-02 | — | — | US | disclosed |
| WO-2003053919-A1 | SUBSTITUTED CYCLOHEXANE DERIVATIVES | F. HOFFMANN-LA-ROCHE AG (CH) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003053933-A1 | HETEROARYL-SUBSTITUTED AMINOCYCLOHEXANE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003029264-A2 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2003-04-10 | — | — | WO | disclosed |
| WO-2002079151-A1 | 3-SUBSTITUTED INDOELS OR FUSED PYRROLES AS ANTAGONISTS OF THE CHEMOKINE MCP-1 (CCR2B) RECEPTOR | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-10-10 | — | — | WO | disclosed |
| EP-0798298-B1 | THIAZOLIDINONE OR OXAZOLIDINONE DERIVATIVES TO TREAT ANGINA PECTORIS OR COMPOSITIONS CONTAINING THE SAME AS ACTIVE INGREDIENT | SANKYO CO (JP) | 2001-08-08 | — | — | EP | disclosed |
| US-5843973-A | Thiazolidinone compounds and composition for angina pectoris comprising the compounds as an active ingredient | SANKYO COMPANY, LIMITED (JP) | 1998-12-01 | — | — | US | disclosed |
| EP-0798298-A1 | THIAZOLIDINONE COMPOUNDS OR ANGINA PECTORIS REMEDY OR PREVENTIVE CONTAINING THE SAME AS ACTIVE INGREDIENT | SANKYO COMPANY LIMITED (JP) | 1997-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117572-A1 | SMALL MOLECULE INHIBITORS OF ULK1 | ULK1, ULK2, ULK3 | FKBP1A 2815/4885NR1H2 4059/4885LRRK2 1191/4885 |
| US-20030186984-A1 | Substituted cyclohexane derivatives | CYP51A1, LSS, CYP46A1 | FKBP1A 2399/4885NR1H2 25/4885LRRK2 4454/4885 |
| US-12473284-B2 | Small molecule inhibitors of ULK1 | ULK1, ULK2, ULK3 | FKBP1A 2815/4885NR1H2 4059/4885LRRK2 1191/4885 |
| US-20030199550-A1 | Substituted cyclohexane derivatives | CYP51A1, LSS, CYP46A1 | FKBP1A 1932/4885NR1H2 22/4885LRRK2 4698/4885 |
| US-20250051347-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | AR, ADRM1, MDM2 | FKBP1A 2328/4885NR1H2 562/4885LRRK2 873/4885 |
| US-20030186926-A1 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | ADORA2A, ADORA1, ADORA3 | FKBP1A 3350/4885NR1H2 1201/4885LRRK2 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.